Zaki Hosny

Nessuna posizione attualmente

75 anni

Health Technology

Consumer Services

Profilo

Zaki Hosny formerly worked at Motif BioSciences, Inc., as Chief Executive Officer & Deputy Chairman from 2011 to 2013, Motif Bio Plc, as Independent Non-Executive Director from 2006 to 2019, and Merck & Co., Inc., as Principal from 1998 to 2007.
Mr. Hosny received his graduate degree from the University of Cambridge.

Precedenti posizioni note di Zaki Hosny

Società	Posizione	Fine
MOTIF BIO PLC	Direttore/Membro del Consiglio	15/11/2019
MERCK & CO., INC.	Corporate Officer/Principal	01/01/2007
Motif BioSciences, Inc. Motif BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Motif BioSciences, Inc. develops antibiotics designed to be effective against serious and life-threatening infections. The company was founded on June 8, 2004 and is headquartered in New York, NY.	Presidente	26/06/2013

Vedi nel dettaglio l'esperienza di Zaki Hosny

Formazione di Zaki Hosny

University of Cambridge

Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Zaki Hosny

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
MERCK & CO., INC.	Health Technology

Aziende private	2
Motif BioSciences, Inc. Motif BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Motif BioSciences, Inc. develops antibiotics designed to be effective against serious and life-threatening infections. The company was founded on June 8, 2004 and is headquartered in New York, NY.	Health Technology
Motif Bio Plc Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ.	Health Technology